Effects of a Non-Calcium Based Phosphate Binder on FGF23 Levels in Chronic Kidney Disease
Status:
Completed
Trial end date:
2014-02-27
Target enrollment:
Participant gender:
Summary
Fibroblast Growth Factor 23 (FGF23) is a molecule that has been implicated in the homeostasis
of phosphorus. Elevated FGF23 levels are well-documented in patients with Chronic Kidney
Disease (CKD) and are inversely correlated with Glomerular Filtration Rate (GFR). FGF23
levels are also predictive of progression of CKD and predict mortality in CKD. Although
studies in normal individuals suggest that phosphorus intake is related to FGF23 levels, the
effect of dietary and pharmacologic phosphate restriction on FGF23 levels in patients with
CKD has never been reported. Our objectives are to determine if phosphate reduction through
the use of non-calcium based phosphate binder will decrease serum FGF23 levels. The
investigators will also be investigating associations of elevation in FGF 23 levels with
commonly encountered co-morbidities in CKD patients such as Coronary Artery Disease, Diabetes
Mellitus, and Hypertension.
Phase:
Early Phase 1
Details
Lead Sponsor:
Milton S. Hershey Medical Center Penn State University